Artwork

内容由Proactive Investors提供。所有播客内容(包括剧集、图形和播客描述)均由 Proactive Investors 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal
Player FM -播客应用
使用Player FM应用程序离线!

Healthcare outlook 2025: healthcare and biotech to regain investor focus

6:17
 
分享
 

Manage episode 461207170 series 2891889
内容由Proactive Investors提供。所有播客内容(包括剧集、图形和播客描述)均由 Proactive Investors 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal
The healthcare and biotech sectors are set to regain investor interest in 2024 due to long-term growth prospects, aided by structural drivers such as ageing populations and rising healthcare expenditure. Healthcare now contributes 10.2% of global GDP, with annual spending expected to reach $14 trillion by 2030. Previously overshadowed by technology, healthcare is now viewed as undervalued following small-cap underperformance last year. Anteris Technologies Global Corp (ASX:AVR, OTC:AMEUF) is advancing its DurAVR® Transcatheter Heart Valve to treat severe aortic stenosis, supported by an $88.8 million Nasdaq IPO to fund further development and clinical trials. Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) is focused on synthetic anti-infectives targeting antibiotic-resistant bacteria and viral infections. Its flagship candidate, RECCE® 327, has received approval for a Phase 3 trial in Indonesia for diabetic foot infections, opening commercial avenues in the ASEAN region. Tryptamine Therapeutics Ltd (ASX:TYP, OTC:TYPTF) develops psilocin-based treatments for neuropsychiatric disorders. Interim results from a Phase 2A trial show potential for addressing Irritable Bowel Syndrome. Orthocell Ltd (ASX:OCC, OTC:ORHHF) targets regenerative medicine, with approved products such as Remplir™ for nerve repair and Striate Plus™ for dental applications. The company aims to expand into the US and other global markets. Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) specialises in rapid diagnostic tests. Its products, FebriDx® and ViraDx™, have received FDA approval, with ongoing efforts to expand within women’s health diagnostics. #HealthcareSector #Biotech #MedicalDevices #DrugDevelopment #RegenerativeMedicine #Diagnostics #BiotechInvesting #GlobalGDP #AorticStenosis #AntibioticResistance #Superbugs #PsilocybinResearch #ChronicPain #NerveRepair #DentalRegeneration #RapidDiagnostics #COVIDTesting #FluTesting #HealthcareInnovation #InvestorOutlook
  continue reading

611集单集

Artwork
icon分享
 
Manage episode 461207170 series 2891889
内容由Proactive Investors提供。所有播客内容(包括剧集、图形和播客描述)均由 Proactive Investors 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal
The healthcare and biotech sectors are set to regain investor interest in 2024 due to long-term growth prospects, aided by structural drivers such as ageing populations and rising healthcare expenditure. Healthcare now contributes 10.2% of global GDP, with annual spending expected to reach $14 trillion by 2030. Previously overshadowed by technology, healthcare is now viewed as undervalued following small-cap underperformance last year. Anteris Technologies Global Corp (ASX:AVR, OTC:AMEUF) is advancing its DurAVR® Transcatheter Heart Valve to treat severe aortic stenosis, supported by an $88.8 million Nasdaq IPO to fund further development and clinical trials. Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) is focused on synthetic anti-infectives targeting antibiotic-resistant bacteria and viral infections. Its flagship candidate, RECCE® 327, has received approval for a Phase 3 trial in Indonesia for diabetic foot infections, opening commercial avenues in the ASEAN region. Tryptamine Therapeutics Ltd (ASX:TYP, OTC:TYPTF) develops psilocin-based treatments for neuropsychiatric disorders. Interim results from a Phase 2A trial show potential for addressing Irritable Bowel Syndrome. Orthocell Ltd (ASX:OCC, OTC:ORHHF) targets regenerative medicine, with approved products such as Remplir™ for nerve repair and Striate Plus™ for dental applications. The company aims to expand into the US and other global markets. Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) specialises in rapid diagnostic tests. Its products, FebriDx® and ViraDx™, have received FDA approval, with ongoing efforts to expand within women’s health diagnostics. #HealthcareSector #Biotech #MedicalDevices #DrugDevelopment #RegenerativeMedicine #Diagnostics #BiotechInvesting #GlobalGDP #AorticStenosis #AntibioticResistance #Superbugs #PsilocybinResearch #ChronicPain #NerveRepair #DentalRegeneration #RapidDiagnostics #COVIDTesting #FluTesting #HealthcareInnovation #InvestorOutlook
  continue reading

611集单集

所有剧集

×
 
Loading …

欢迎使用Player FM

Player FM正在网上搜索高质量的播客,以便您现在享受。它是最好的播客应用程序,适用于安卓、iPhone和网络。注册以跨设备同步订阅。

 

快速参考指南

边探索边听这个节目
播放